Galapagos

Galapagos PEG

The PEG Ratio (Price/Earnings-to-Growth) of Galapagos (GLPG.AS) as of Nov 3, 2026 is 0.02.

PEG

0.02

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Galapagos is 2025 0.02 . PEG Ratio (Price/Earnings-to-Growth) of Galapagos was 2024 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Galapagos Stock analysis

What does Galapagos do? Galapagos NV is a Belgian biopharmaceutical company focused on the development of novel drugs, particularly for autoimmune diseases and fibrosis. The company was founded in 1999 by Onno van de Stolpe and is headquartered in Mechelen, Belgium. Galapagos is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Galapagos stock

PEG Ratio (Price/Earnings-to-Growth) of Galapagos is 0.02 in 2025.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Galapagos since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Galapagos with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Galapagos

All Key Metrics — Galapagos